Last reviewed · How we verify
Matched-Placebo for Tafenoquine
Tafenoquine is an antimalarial drug that works by targeting the parasite's heme detoxification pathway.
Tafenoquine is an antimalarial drug that works by targeting the parasite's heme detoxification pathway. Used for Treatment of malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae, Prevention of malaria caused by Plasmodium falciparum.
At a glance
| Generic name | Matched-Placebo for Tafenoquine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | 8-aminoquinoline |
| Target | Plasmodium heme detoxification pathway |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Tafenoquine is a blood schizonticide that inhibits the parasite's ability to detoxify heme, ultimately leading to the parasite's death. This mechanism of action is thought to be responsible for the drug's efficacy against Plasmodium species.
Approved indications
- Treatment of malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae
- Prevention of malaria caused by Plasmodium falciparum
Common side effects
- Hemolysis
- Neuropsychiatric events
- Gastrointestinal disturbances
Key clinical trials
- A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression (PHASE2)
- Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria (PHASE3)
- Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matched-Placebo for Tafenoquine CI brief — competitive landscape report
- Matched-Placebo for Tafenoquine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI